Giancarlo Benelli reflects on why Europe must capitalise on its strong innovative drug discovery infrastructure by shoring up the last mile and attracting clinical trials back to Europe’s healthcare systems.
The definitive guide to transitioning from manual, offline batch testing to automated, continuous biomanufacturing.
During this webinar industry experts will share practical insight and considerations for modernising pharmaceutical downstream workflows.
Cell and gene therapies are transforming modern medicine, offering new hope for patients with complex and previously untreatable diseases. As innovation advances, the industry must overcome challenges in manufacturing, regulation and scalability to unlock the full potential of these groundbreaking therapies.
Investment at Lonza’s facility in Visp, Switzerland designed to meet increasing demand in the ADC market.
The two-step synthesis process offers a streamlined approach that removes longstanding barriers to scalable C-glycoside manufacture for SGLT2 inhibitors.
Research provides a data-driven foundation for excipient selection in drug formulation development, particularly solid dosage forms.
FDA’s approval of generic baloxavir marboxil tablets for influenza broads access to a novel-mechanism antiviral for individuals aged five years and over.
Manual sampling cycles leave bioreactor control decisions hours behind culture dynamics. Process Raman spectroscopy offers continuous, real-time measurement of critical parameters, enabling true closed-loop control in perfusion and continuous bioprocessing applications where measurement lag directly impacts yield and product quality.